CD133及CD44在肺癌组织中表达及其与临床病理学特征和预后的关系

Expressions of CD133 and CD44 in lung cancer tissues and their relationship with clinicopathological features and prognosis

目的 探讨CD133及CD44在肺癌组织中表达及其与临床病理学特征和预后的关系。方法 采用免疫组化和Western-Blot方法检测73例肺癌组织标本及其对应61例癌旁正常组织标本中CD133及CD44表达情况,分析CD133及CD44表达与临床病理特征的关系,探讨二者表达与患者预后关系。结果 CD133、CD44肺癌组织中主要表达于肿瘤细胞质,阳性细胞呈棕黄色颗粒分布,CD133在肺癌组织中阳性表达率为60.27%(44/73),显著高于癌旁组织中阳性表达率的8.20%(5/61)(P<0.05);CD44在肺癌组织中阳性表达率为65.75%(48/73),显著高于癌旁组织中阳性表达率的13.11%(8/61)(P<0.05);肺癌组织中CD133、CD44蛋白表达水平明显高于对应癌旁组织(P<0.05);鳞癌患者CD44表达水平明显高于腺癌、小细胞癌患者(P<0.05),发生淋巴结远处转移肺癌患者CD133及CD44表达水平明显高于未发生淋巴结远处转移患者(P<0.05),CD133表达水平与肺癌患者性别、年龄、临床TNM分期、肿瘤直径、病理类型、分化程度无关(P>0.05),CD44表达水平与肺癌患者性别、年龄、临床TNM分期、肿瘤直径、分化程度无关(P>0.05);CD133阳性患者中位生存时间22.86个月(95%CI:20.74,24.99),5年生存率36.36%,CD133阴性患者中位生存时间31.37个月(95%CI:27.31,35.87),5年生存率62.07%,两组生存情况比较,差异有统计学意义(Log-rank χ^2=4.06,P<0.05);CD44阳性患者中位生存时间24.77个月(95%CI:20.74,27.61),5年生存率39.58%,CD44阴性患者中位生存时间32.01个月(95%CI:28.16,35.87),5年生存率68.00%,两组生存情况比较,差异有统计学意义(Log-rank χ^2=3.95,P<0.05)。结论 CD133及CD44在肺癌组织中呈高水平表达,二者表达与肺癌淋巴结转移有关,其表达与患者预后密切相关,有望成为肺癌新的治疗靶点。

Objective To explore the expressions of CD133 and CD44 in lung cancer tissues and their relationship with clinicopathological features and prognosis.Methods Immunohistochemistry and Western-Blot method were used to detect the expressions of CD133 and CD44 in 73 specimens of lung cancer tissues and 61 specimens of normal adjacent tissues.The relationship between expressions of CD133 and CD44 and clinicopathological features was analyzed,and the relationship between expressions of the two and prognosis of patients was explored.Results CD133 and CD44 were mainly expressed in tumor cytoplasm of lung cancer tissues,and the positive cells were distributed in brownyellow particles.The positive expression rate of CD133 in lung cancer tissues was significantly higher than those in adjacent tissues[60.27%(44/73)vs 8.20%(5/61)](P<0.05).The positive expression rate of CD44 in lung cancer tissues was significantly higher than that in adjacent tissues[65.75%(48/73)vs 13.11%(8/61)](P<0.05).The expression levels of CD133 and CD44 protein in lung cancer tissues were significantly higher than those in adjacent tissues(P<0.05).The expression level of CD44 in patients with squamous cell carcinoma was significantly higher than that in patients with adenocarcinoma and small cell carcinoma(P<0.05).The expression levels of CD133 and CD44 in lung cancer patients with distant lymph node metastasis were significantly higher than those in patients without distant lymph node metastasis(P<0.05),and the expression level of CD133 was not related to gender,age,clinical TNM stage,tumor diameter,pathological type and differentiation degree of lung cancer patients(P>0.05),and the expression level of CD44 was not related to gender,age,clinical TNM stage,tumor diameter and differentiation degree of lung cancer patients(P>0.05).The median survival time and 5-year survival rate of CD133-positive patients were 22.86 months(95%CI:20.74,24.99)and 36.36%,and the median survival time and 5-year survival rate of CD133-negative patients were 31.37 months(95%CI:27.31,35.87)and 62.07%,and there was a statistically significant difference in the survival between the two groups(Log-rank χ^2=4.06,P<0.05).The median survival time and 5-year survival rate of CD44-positive patients were 24.77 months(95%CI:20.74,27.61)and 39.58%,and the median survival time and5-year survival rate of CD44-negative patients were 32.01 months(95%CI:28.16,35.87)and 68.00%,and there was a statistically significant difference in the survival between the two groups(Log-rank χ^2=3.95,P<0.05).Conclusion CD133 and CD44 are highly expressed in lung cancer tissues,and their expressions are related to lymph node metastasis of lung cancer.The expressions of CD133 and CD44 are closely related to the prognosis of patients,and they are expected to become new therapeutic targets for lung cancer.